Inogen reports recurring developments as a respiratory medical technology company serving homecare patients with chronic respiratory conditions. Its updates focus on financial results and outlook, portable oxygen concentrators, Simeox airway clearance, stationary oxygen concentrators, and Aurora CPAP masks for obstructive sleep apnea.
Company news also covers product introductions, clinical evidence and reimbursement work, international market activity, commercial partnerships, leadership and board changes, inducement equity awards, share repurchase actions, and investor conference participation.
Inogen, Inc. (Nasdaq: INGN) announced their first quarter 2024 financial results, showing an 8.1% increase in total revenue to $78.0 million, accompanied by a total gross margin of 44.1%. The GAAP net loss was $14.6 million, with adjusted net loss at $10.4 million. Adjusted EBITDA was a negative $7.6 million. Inogen expects revenue for the second quarter of 2024 to be in the range of $81 million to $84 million. The company remains focused on revenue growth, profitability, and innovation to enhance their market position.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.